28 results about "Antigen antibody binding" patented technology

The invention provides an improved hard tissue decalcification solution and application thereof, and relates to the technical field of hard tissue decalcification, the improved hard tissue decalcification solution is obtained by mixing EDTA, ammonia water and water, and Ca < 2 + > ions are jointly chelated by the ammonia water and the EDTA in a water environment; the mass volume ratio of the EDTA to the ammonia water to the water is (140 to 280) g to (20 to 400) mL to (1000 to 2000) mL; the pH value of the improved hard tissue decalcification liquid is 6.5-7.5, the decalcification speed is accelerated by accurately controlling the pH value, the decalcification period is shortened by about 50%, it is guaranteed that antigen-antibody combination is not affected after decalcification, mild decalcification is achieved, and a high-quality sample is provided for subsequent histological research.

Embodiments of the present disclosure disclose an antigen-antibody binding conformation optimization method and device based on iterative closest point. A specific embodiment of the method comprises: obtaining a coarse-grained antibody file and a coarse-grained antigen file; performing surface residue extraction on the antigen structure file and the antibody structure file to obtain an antigen surface residue information set and an antibody surface residue information set; generating an antibody binding region residue list; generating an epitope model; performing spatial matching on the antigen surface residue information set and the epitope model to obtain a matched epitope model; generating an antibody docking conformation set; performing local optimization on each antibody docking conformation in the antibody docking conformation set to obtain an optimized antibody conformation set; and screening each optimized antibody conformation in the optimized antibody conformation set to obtain a target antigen-antibody binding conformation. The embodiment can improve the accuracy of the antibody conformation.

The application discloses a method and device for controlling liquid reciprocating flow based on magnetic force and application. The method provided by the application utilizes the interfacial capillary force generated by the hydrophilic magnet on the gas / liquid / solid three-phase interface formed before the liquid is separated to realize the flow control of the liquid. The method has the advantages of: 1) non-contact flow control, which can avoid the pollution caused by contact control (such as mechanical probe control); 2) the liquid is moved smoothly and quickly, no bubbles and new gas-liquid interfaces are generated, the severe friction and vibration on the gas-liquid interface are avoided, and the aerosol generation probability is reduced; 3) compared with the existing magnetic control mode for moving or disturbing the liquid by pushing force, the aerosol pollution risk is greatly reduced. In addition, the beneficial effects of only 1-2 minutes for one round of antigen-antibody combination and 5-15 minutes for one detection are realized, and the detection speed is much higher than that of the traditional immunodetection method based on a reaction cup or a microhole plate.

The invention provides a Pirin-targeted nano antibody and application thereof. The nano antibody comprises a complementary determining region CDR which is a CDR1 shown in SEQ ID NO: 1 and a CDR3 shown in SEQ ID NO: 2, or a CDR1 shown in SEQ ID NO: 10 and a CDR3 shown in SEQ ID NO: 11, and an HV2 shown in an amino acid sequence of SEQ ID NO: 3 and an HV4 shown in an amino acid sequence of SEQ ID NO: 4, or an HV2 shown in SEQ ID NO: 12 and an HV4 shown in SEQ ID NO: 13. The KD value of the nano antibody is in a range of 2.0-15nM, the nano antibody has antigen-antibody binding force, the affinity is close to a nanomole level, and the nano antibody can be regarded as a high-affinity antibody; the compound can be developed into a high-specificity diagnostic reagent, and can be used as a therapeutic drug or an immune sensitizer.

The invention discloses an optical weak measurement molecular detection system and method for helicobacter pylori antibody detection. In the system, a light source module generates a uniform polarized light field. And the polarization state regulation and control module utilizes a front selection polaroid and a rear selection polaroid to enhance an antigen-antibody binding signal through a weak value amplification effect. A helicobacter pylori specific antibody is fixed on a prism structure of the sensor module, and interface refractive index change is caused after the helicobacter pylori specific antibody is combined with a sample antigen. The imaging module captures a modulated light intensity signal in real time, and converts refractive index change into light intensity response. And the data processing module performs baseline calibration and signal analysis, and establishes a quantitative relationship between antigen concentration and optical response. The system realizes non-label detection through optical path coupling and weak measurement, and completes quantitative analysis of the antibody by utilizing optical signal feature extraction. The system has the advantages of being ultrahigh in sensitivity, excellent in anti-interference performance, easy and convenient to operate and the like, and a solution with scientific research precision and practical value is provided for large-scale helicobacter pylori screening.

The application relates to an AI-assisted result interpretation micro-sample detection kit for cutaneous leishmaniasis infection and an antibody detection method, and belongs to the technical field of serological immunodetection. The kit comprises an antibody detection platform for micro-samples, micro-bead probes, a washing solution, an antibody diluent, F594-labeled sheep anti-rat antibodies, positive quality control serum and negative quality control serum; the spherical probes are adopted in the application, the antigen-antibody combination efficiency is improved in space, and the antigen-antibody collision probability is effectively improved. Meanwhile, the micro-beads form a micro-scale mass transfer network in the reaction cavity, fluid mixing is enhanced, the reaction time is shortened, and the overall residence time and consumption of samples and reagents in the microfluidic channel are reduced. The application also introduces an AI-assisted result interpretation system to assist in result interpretation, significantly improves the friendliness and accessibility of the detection process, the classification model based on artificial intelligence has stronger robustness and judgment consistency, and has good market development value and popularization and application prospect.

The invention discloses a latex enhanced immunoturbidimetry detection reagent for glycosylated hemoglobin and a use method of the latex enhanced immunoturbidimetry detection reagent, and relates to the technical field of medical examination. The latex enhanced immunoturbidimetry detection reagent for glycosylated hemoglobin comprises a reagent R1 and a reagent R2, wherein the reagent R1 comprises first nano microspheres; and the reagent R2 comprises a second nano microsphere coated with a monoclonal antibody of HbA1c. According to the reagent R2, the nano microspheres are coated with the monoclonal antibody of HbA1c, the stability risk caused by the fact that balance needs to be established for immunoreaction of multiple antibodies and antigens is avoided through the monoclonal antibody, the problem that a glycosylated hemoglobin immunoturbidimetry detection reagent is insufficient in stability can be solved, the nano microspheres are arranged on the reagent R2, and therefore the stability of the glycosylated hemoglobin immunoturbidimetry detection reagent is improved, and the stability of the glycosylated hemoglobin immunoturbidimetry detection reagent is improved. By utilizing the characteristic that the volume of an antigen-antibody conjugate can be increased after the nano-microspheres are combined with the HbA1c monoclonal antibody, the turbidimetric degree of latex is effectively amplified, and the detection sensitivity can be improved.

The invention relates to the technical field of biology, and particularly discloses a method for removing H3K27me3 in a plant by using a SunTag system. The method provided by the invention comprises the following steps: based on a SunTag system, the system comprises dcas9 protein-antigen protein GCN4 started by UBQ10; antibody protein scFv-sfGFP and guide RNA (Ribonucleic Acid). According to the system, through the guiding effect of gRNA, effect protein recruitment can be carried out on a specific site in an antigen-antibody binding mode. The editing method has a certain activation effect on genes which are modified by H3K27me3 and are expressed silently, a new thought and a new means are provided for plant gene function research and crop genetic improvement, deep understanding of a plant gene expression regulation mechanism is facilitated, and progress of plant breeding and agricultural production is promoted.

This invention discloses a fluorescence detection data analysis method based on antigen-antibody specific recognition, applied in the field of data processing technology. The invention acquires multi-source analysis data, including fluorescence signal time-series data and antigen-antibody binding reaction records, and preprocesses core elements based on a recognition threshold and feature weights set by affinity to obtain a standardized dataset. Then, the core data and auxiliary data are sorted according to their correlation with specific recognition. An analysis strategy is determined based on dataset complexity, device computing power, and algorithm characteristics, and the data is split into analysis batches. After importing the data through a parallel mechanism, a multimodal feature fusion algorithm is used, relying on the principle of antigen-antibody specific recognition. The analysis parameters are optimized by combining three types of feature weighted fusion logic, dynamically adapting the core parameters. The core algorithm combines feature extraction from a kinetic model with fluorescence signal specificity matching verification to achieve accurate detection and analysis.

The utility model discloses a colloidal gold immunochromatography analyzer with a test paper pop-up structure, which relates to the technical field of colloidal gold immunochromatography analyzers and comprises an analyzer shell and a connecting seat, and the head end of the connecting seat is telescopically mounted in the analyzer shell. A telescopic guide mechanism for limiting the telescopic speed of the connecting seat is mounted in the analyzer shell and mainly comprises a cylinder barrel, an oil tank, a push rod, a piston, a three-way pipe and a throttling bolt; according to the utility model, the telescopic speed of the connecting seat is limited by the telescopic guide mechanism, so that the colloidal gold test card in the connecting seat is effectively prevented from shaking due to rapid movement; in the detection process, a sample is prevented from being interfered by migration on a membrane in the colloidal gold test card, the stability of an antigen-antibody binding process is ensured, and the risk of incomplete reaction or non-specific binding is reduced, so that the accuracy of a detection result is remarkably improved.

The invention provides a DeepVent-targeted nano antibody and application thereof. The nano antibody comprises a complementary determining region CDR (complementary determining region) which is CDR1 as shown in SEQ ID NO: 1, CDR3 as shown in SEQ ID NO: 2, HV2 as shown in an amino acid sequence as shown in SEQ ID NO: 3 and HV4 as shown in an amino acid sequence as shown in SEQ ID NO: 4. The KD value of the nano antibody is in a range of 2.0-15nM, the nano antibody has antigen-antibody binding force and affinity close to nanomole level, can be regarded as a high-affinity antibody, can be used for production and quality control, can be used for developing a next-generation'hot start 'PCR (polymerase chain reaction) reagent, and can be developed into a reversible and temperature-sensitive inhibitor.

The invention provides a nano antibody targeting an RBD structural domain of novel coronavirus spike protein and application of the nano antibody. The nanometer antibody comprises a complementary determining region CDR which is a CDR1 shown in SEQ ID NO: 1 and a CDR3 shown in SEQ ID NO: 2, or a CDR1 shown in SEQ ID NO: 10 and a CDR3 shown in SEQ ID NO: 11, or a CDR1 shown in SEQ ID NO: 18 and a CDR3 shown in SEQ ID NO: 18 and a CDR3 shown in SEQ ID NO: 25, and an HV2 shown in an amino acid sequence of SEQ ID NO: 3 and an HV4 shown in an amino acid sequence of SEQ ID NO: 4, or an HV2 shown in SEQ ID NO: 12 and an HV4 shown in SEQ ID NO: 13, or an HV2 shown in SEQ ID NO: 20 and an HV4 shown in SEQ ID NO: 4. The KD value of the nano antibody is in a range of 2.0-15nM, the nano antibody has antigen-antibody binding force and affinity close to nanomole level, and the nano antibody can be regarded as a high-affinity antibody and is used for developing a neutralizing antibody therapeutic drug of a targeted virus invasion mechanism and constructing a high-specificity serological diagnostic reagent and a variant monitoring platform.

This application discloses a method for detecting CHI3L1 protein based on microfluidic fiber optic sensing, belonging to the field of biomedical detection technology. The method includes: providing a microstructured fiber optic sensing unit with a through-flow microfluidic channel; immobilizing a CHI3L1 protein-specific antibody on the inner surface of the microfluidic channel; injecting the sample to be tested into the channel, causing the CHI3L1 protein to be specifically captured; and achieving quantitative detection of the CHI3L1 protein by detecting the drift of fiber optic transmission spectral characteristic parameters caused by antigen-antibody binding. This invention combines microfluidics with fiber optic sensing, utilizing antibody immobilization on the inner wall of the microfluidic channel to increase the interaction efficiency between the light field and biomolecules, significantly improving detection sensitivity. It has the advantages of rapid detection, low sample consumption, and label-free operation, making it suitable for early non-invasive screening and dynamic monitoring of clinical liver fibrosis.

The invention belongs to the technical field of biomacromolecule separation and purification, and particularly relates to an LH antibody affinity chromatography column as well as a preparation method and application thereof. According to the key principle of antigen-antibody combination, an NHS (N-hydroxysuccinimide) group is activated by an NHS 4FF chromatography filler, and then an LH antibody is combined to serve as a ligand to prepare the LH antibody affinity chromatography filler. By using the LH antibody affinity chromatography filler, the high-purity urofollicle-stimulating hormone (pFSH) is prepared from a drug raw material menotrophin (HMG) through 30 KD ultrafiltration. The result of the embodiment shows that the specific activity of high-purity urofollicle-stimulating hormone (pFSH) prepared by using the LH antibody affinity chromatography filler is greater than 15000 IU / mg protein, the ratio of LH to FSH is less than 0.05: 100.00, impurities such as impure protein are less, luteinizing hormone (LH) is more completely removed, and the product is safer and more efficient.

Disclosed are a BAFFR-targeting chimeric antigen receptor, a CAR-T cell, and a use. The BAFFR-targeting chimeric antigen receptor comprises a signal peptide region, a BAFFR-targeting antigen binding domain, a hinge region, a transmembrane domain, a costimulatory domain, and a signal transduction domain, which are connected in order from the amino terminal to the carboxyl terminal, wherein the costimulatory domain comprises a CD28 costimulatory domain and a 4-1BB costimulatory domain which are connected, and the signal transduction domain is ITAM1 of CD3ζ. The CAR-T cell is constructed by means of BAFFR. By utilizing an antigen-antibody binding mechanism, autoimmune B cells or malignant proliferating B cells in patients with autoimmune diseases or some tumors can be effectively consumed, providing a new choice for the treatment of human autoimmune related diseases and some hematologic tumors.

This invention relates to the field of biotechnology and discloses a method for detecting intact, live pathogens in samples. The invention provides a rapid detection method for intact, live pathogens based on specific immunomagnetic beads and microfluidic chips, and constructs an automated, multiplexed detection system. Its core lies in combining three key steps—"specific capture of intact pathogens," "active signal screening," and "rapid and sensitive detection"—with a microfluidic chip technology platform. This transforms the protein signal of antigen-antibody binding into a nucleic acid amplification signal, improving sensitivity and enabling direct, rapid, and accurate identification of infectious live pathogens from complex samples, thus demonstrating broad application prospects.

The invention provides an anti-human PD-1 monoclonal antibody with agonistic activity or an antigen binding fragment thereof and application of the anti-human PD-1 monoclonal antibody. The anti-human PD-1 monoclonal antibody with agonistic activity or the antigen binding fragment thereof is characterized in that a mouse is immunized through in-vitro recombinant expression of protein antigens of human PD-1 Fc and his tags, spleen, bone marrow and lymph node cells of the mouse are collected, and plasma cells of a secreting target cell binding antibody are enriched by adopting a microfluidic droplet sorting system; carrying out single-cell library construction on plasma cells, and carrying out NGS sequencing to obtain antibody sequences naturally paired with light and heavy chains; the method comprises the following steps: selecting an antibody sequence to carry out mammalian cell high-throughput expression, carrying out ELISA detection, flow detection and reporter gene cell line verification, selecting a representative antibody to carry out animal in-vivo experiment verification, and carrying out screening verification to obtain a series of anti-human PD-1 monoclonal antibodies with agonistic activity or antigen binding fragments thereof. The polypeptide has high affinity and high specificity, and has good antigen-antibody binding activity and agonistic activity on the cellular level.

The present invention discloses a method for obtaining allosteric regulation of the receptor-binding domain of the SARS-CoV-2 S protein by distal residues based on computer simulation. First, the structures of the S protein in different states when bound and unbound to antibodies are obtained, and a protein solvation model is constructed; secondly, energy minimization, pre-equilibration, and molecular dynamics simulations are performed to obtain the simulation trajectories of each system; then, dynamic network analysis is carried out, and each domain is regarded as a rigid body, and the dihedral angle is calculated by the line connecting the centers of mass of each domain to obtain the macroscopic domain change trend; residue free energy decomposition is performed to obtain the residues that contribute more in antigen-antibody binding, which are more likely to trigger deeper regulation during the binding process; finally, time-delay independent component analysis is performed on the change characteristics of the simulation trajectories, and the contribution of each residue to the change of the trajectory is scored to obtain the regulatory effect of the residue on the trajectory change, providing a new idea for the treatment target of the SARS-CoV-2 S protein.

The invention provides a pIIIa-targeted nano antibody and application thereof. The nano antibody comprises a complementary determining region CDR (complementary determining region) which is CDR1 as shown in SEQ ID NO: 1 and CDR3 as shown in SEQ ID NO: 2, HV2 as shown in an amino acid sequence as shown in SEQ ID NO: 3 and HV4 as shown in an amino acid sequence as shown in SEQ ID NO: 4. The KD value of the nano antibody is in a range of 2.0-15nM, the nano antibody has antigen-antibody binding force, the affinity is close to a nanomole level, and the nano antibody can be regarded as a high-affinity antibody; the kit can be used as a diagnostic reagent, an antiviral drug and a bacteriophage display quality control tool.

The invention provides a multi-microsphere ratio optimization method for immunodetection, which belongs to the technical field of microspheres for immunodetection, and comprises the following steps: firstly, collecting microsphere surface molecular modification data including antibody density, antigen coupling ratio and the like, and measuring molecular action parameters including antigen-antibody binding constant and the like; cross reaction detection is carried out through orthogonal test design, and a multi-microsphere cross reaction evaluation model is established. And then constructing a performance optimization model based on an embedded neural network, establishing a mapping relation between the surface molecular modification data and a proportioning scheme, and calculating an optimal proportioning scheme. And then establishing a matrix effect model based on an improved residual network, analyzing matrix component influence in a clinical sample, and performing result correction. And finally, collecting performance degradation data of the microsphere system under different environmental conditions, establishing a stability prediction model by using the improved recurrent neural network, predicting the validity period of the microsphere system, and optimizing concentration parameters in the proportioning scheme according to the validity period to obtain a final proportioning scheme.

The invention relates to the technical field of electrochemical immunosensors, and discloses composite modification liquid, an electrochemical immunosensor and application of the electrochemical immunosensor. The composite modification liquid provided by the invention is prepared from carboxylated multi-walled carbon nanotubes, a two-dimensional nanomaterial, polyvinyl alcohol, poly (3, 4-ethylenedioxythiophene) and polystyrene sulfonate as raw materials, and all the components have a synergistic effect to jointly construct a solid-phase sensing interface with high conductivity, large specific surface area and excellent biocompatibility; when the composite modification liquid is used for preparing an electrochemical immunosensor, a solid composite membrane formed by drying greatly promotes the electron transfer rate and provides abundant sites for antibody fixation, and a biological recognition event is efficiently converted into sensitive electric signal change through a steric hindrance effect generated after antigen-antibody combination, so that the electrochemical immunosensor has high sensitivity. When being applied to osteocalcin detection, the compound shows an ultra-wide linear range and an extremely low detection limit, and also has excellent selectivity, reproducibility and long-term stability, high detection efficiency and low cost.

The application belongs to the technical field of molecular biology, and particularly relates to an anti-human CCR8 monoclonal antibody and a preparation method thereof. The anti-human CCR8 monoclonal antibody of the application comprises VHCDR1, VHCDR2 and VHCDR3 with the amino acid sequences shown in SEQ ID NO: 1-3; and VLCDR1, VLCDR2 and VLCDR3 with the amino acid sequences shown in SEQ ID NO: 4-6. The antibody development process is as follows: Human CCR8 mRNA is synthesized, mice are immunized, and mouse spleen, bone marrow and lymph node cells are collected; a microfluidic droplet sorting system is used to wrap single plasma cell suspension, fluorescently labeled secondary antibody and Human CCR8 HEK293 overexpression cell line in water-in-oil droplets, and dielectrophoresis sorting is performed to enrich plasma cells secreting target cell binding antibodies; single cell library construction is performed on the plasma cells, and NGS sequencing is performed to obtain light and heavy chain naturally paired antibody sequences; the antibody sequences are selected for mammalian cell high-throughput expression, and flow cytometry detection verification is performed. The monoclonal antibody of the application has good antigen-antibody binding activity and specificity at the cell level.

The invention discloses an antibody antigen affinity prediction method and system based on a protein language model, and the method comprises the steps: (1) sequence splicing: splicing a heavy chain variable region and a light chain variable region of an antibody and an antigen sequence into an affinity sequence according to a preset sequence for antigen-antibody data to be judged; the antigen-antibody data comprises an antigen sequence, an antibody heavy chain variable region sequence and an antibody light chain variable region sequence; (2) coding the large language model: inputting the affinity sequence into the large protein language model, and taking the output vector or the average value of the output quantity of a coding layer of the large protein language model as affinity coding; and (3) antigen-antibody binding judgment: inputting affinity codes into a classifier to judge whether antigen-antibody data can be bound or not. According to the method, surprising judgment accuracy is obtained on a small training sample data set, and compared with a classifier based on other sequence feature extraction modes, the judgment accuracy is greatly improved.

The invention provides a p53OD-targeting nano antibody and an application thereof. The nano antibody comprises a complementary determining region CDR which is a CDR1 shown in SEQ ID NO: 1 and a CDR3 shown in SEQ ID NO: 2, or a CDR1 shown in SEQ ID NO: 1 and a CDR3 shown in SEQ ID NO: 10, or a CDR1 shown in SEQ ID NO: 16 and a CDR3 shown in SEQ ID NO: 17, and an HV2 shown in an amino acid sequence of SEQ ID NO: 3 and an HV4 shown in an amino acid sequence of SEQ ID NO: 4, or an HV2 shown in SEQ ID NO: 11 and an HV4 shown in SEQ ID NO: 12, or an HV2 shown in SEQ ID NO: 18 and an HV4 shown in SEQ ID NO: 19. The KD value of the nano antibody is in a range of 2.0-15nM, the nano antibody has antigen-antibody binding force and affinity close to nanomole level, can be regarded as a high-affinity antibody, can be used as an accompanying tool for optimizing and monitoring p53OD drugs, can be coupled with the drugs, and is used for synergistic interaction treatment.

The embodiment of the invention discloses an antigen-antibody binding conformation optimization method and device based on an iterative closest point. A specific embodiment of the method comprises the following steps: obtaining a coarse graining antibody file and a coarse graining antigen file; performing surface residue extraction on the antigen structure file and the antibody structure file to obtain an antigen surface residue information set and an antibody surface residue information set; generating an antibody binding region residue list; generating an epitope model; performing spatial matching on the antigen surface residue information set and the epitope model to obtain a matched epitope model; generating an antibody docking conformation set; performing local optimization on each antibody docking conformation in the antibody docking conformation set to obtain an optimized antibody conformation set; and screening each optimized antibody conformation in the optimized antibody conformation set to obtain a target antigen-antibody binding conformation. According to the embodiment, the accuracy of antibody conformation can be improved.

The object of the present application is to provide a method, device, medium and program product for predicting antigen epitope information. The method includes: determining antigen surface atom information and antibody surface atom information respectively based on the antigen information to be docked and the antibody information to be docked; determining corresponding antigen block information and antibody block information respectively based on the antigen surface atom information and the antibody surface atom information; and determining corresponding antigen epitope information by using a corresponding deep learning network based on the antigen block information and the antibody block information. The present application focuses on the surface information in the process of antigen-antibody binding, and predicts antigen epitopes by learning the surface information in antigen-antibody binding, thereby improving the prediction efficiency and accuracy.

The present application relates to a CD7-based humanized chimeric antigen receptor and use thereof, specifically a method for constructing chimeric antigen receptor T (CAR-T) cells based on a tumor-specific target CD7 and use thereof in anti-tumor therapy. The chimeric antigen receptor includes an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3ζ signaling domain, which are connected in tandem; where the antigen binding domain binds to a tumor surface antigen, and the tumor surface antigen is CD7. The humanized chimeric antigen receptor of the present application performs particular gene modification on a single-chain antibody specific to an antigen CD7. The modified humanized single-chain antibody has a stronger antigen-antibody binding ability, and the chimeric antigen receptor stimulates T cells better, is maintained longer in vivo, and has a better targeting effect than other CD7 chimeric antigen receptors so that the therapeutic effect of CAR-T cells is enhanced.

The embodiments of the present disclosure provide a method, apparatus, device and computer-readable storage medium for determining an antigen-antibody binding site. The method provided by the embodiments of the present disclosure determines the structural similarity and sequence similarity of the antibody to be predicted with other known antibodies based on the key regions of the antibody by combining the sequence information and structural information of the antibody, and predicts the binding site of the known antibody and antigen that is most similar to the antibody to be predicted as the binding site of the antibody to be predicted and the antigen, thereby achieving accurate prediction of the antibody binding site. The method of the embodiments of the present disclosure can assist antibody drugs for specific binding sites, and quickly and accurately predict changes in binding sites caused by antigen mutations, thereby accelerating the research and development of vaccines or antibody drugs.